Suzhou Genhouse Bio Co., Ltd.

Beijing, Beijing Municipality

OncologyPhase I

What changed

NIH R01 · $0.6M · A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment

7mo agoGrant renewalDec 8, 2025Source filing (opens the source filing in a new tab)

Momentum

52no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1 registered
Mar 27, 2025
Advanced Solid Tumor Cancer · ACTIVE_NOT_RECRUITING · sponsor: Suzhou Genhouse Bio Co., Ltd. · A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
ClinicalTrials.gov · NCT07260513 (opens the source filing in a new tab)
Grant
R01 · $571k · non-dilutive
Dec 1, 2023
UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHOU, CHUAN · NCI · award ends Nov 30, 2028 · A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment
NIH RePORTER · NIH RePORTER 11233268 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 1.00name similarity 100% · semantic similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.6M · A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment
7mo agoGrant renewalSource (opens the source filing in a new tab)
Phase I trial registered: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
7mo agoTrial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1 registered

R01 · $571k · non-dilutive